Eton Pharmaceuticals’ (ETON) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Eton Pharmaceuticals (NASDAQ:ETON) in a research note published on Wednesday morning,Benzinga reports. The brokerage currently has a $11.00 price objective on the stock. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q1 2025 earnings at $0.09 EPS, Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.14 EPS, FY2026 earnings at $0.85 EPS, FY2027 earnings at $1.13 EPS and FY2028 earnings at $1.28 EPS.

Separately, Craig Hallum upped their target price on shares of Eton Pharmaceuticals from $10.00 to $15.00 and gave the company a “buy” rating in a report on Monday, October 28th.

Eton Pharmaceuticals Stock Down 4.2 %

Shares of ETON opened at $10.02 on Wednesday. The company has a market capitalization of $258.92 million, a price-to-earnings ratio of -45.55 and a beta of 1.25. Eton Pharmaceuticals has a 52-week low of $3.03 and a 52-week high of $11.11. The stock has a 50 day moving average price of $7.40 and a 200 day moving average price of $4.99.

Insider Activity

In other Eton Pharmaceuticals news, major shareholder Opaleye Management Inc. bought 11,248 shares of the stock in a transaction dated Monday, October 7th. The shares were acquired at an average cost of $7.22 per share, for a total transaction of $81,210.56. Following the completion of the transaction, the insider now owns 2,730,000 shares in the company, valued at approximately $19,710,600. The trade was a 0.41 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders bought 85,600 shares of company stock valued at $462,674. Insiders own 14.89% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ETON. Geode Capital Management LLC grew its holdings in shares of Eton Pharmaceuticals by 13.5% during the third quarter. Geode Capital Management LLC now owns 272,696 shares of the company’s stock worth $1,637,000 after buying an additional 32,365 shares during the last quarter. Jane Street Group LLC acquired a new stake in Eton Pharmaceuticals during the 3rd quarter worth approximately $90,000. Parkman Healthcare Partners LLC grew its stake in shares of Eton Pharmaceuticals by 2.8% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock valued at $1,561,000 after purchasing an additional 7,029 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Eton Pharmaceuticals in the 3rd quarter valued at approximately $54,000. Finally, Wasatch Advisors LP acquired a new position in shares of Eton Pharmaceuticals in the third quarter valued at approximately $1,431,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.